Letter to the Editor: Clarification of Evidence and Consensus on Strengthening Pharmacovigilance for Vaccine Safety.
作者信息
Kim Hye Young
机构信息
Medical Affairs, SK bioscience Co. Ltd., Seongnam, Korea.
出版信息
J Korean Med Sci. 2024 Dec 2;39(46):e333. doi: 10.3346/jkms.2024.39.e333.
Abstract
摘要
相似文献
1
Letter to the Editor: Clarification of Evidence and Consensus on Strengthening Pharmacovigilance for Vaccine Safety.致编辑的信：关于加强疫苗安全性药物警戒的证据与共识的澄清
J Korean Med Sci. 2024 Dec 2;39(46):e333. doi: 10.3346/jkms.2024.39.e333.
2
Letter to the editor regarding "Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database".致编辑的信：关于“erenumab、galcanezumab和fremanezumab在妊娠和哺乳期的安全性概况：世界卫生组织药物警戒数据库分析”
Cephalalgia. 2021 Sep;41(10):1128-1129. doi: 10.1177/03331024211006827. Epub 2021 May 2.
3
Pharmacovigilance capacity strengthening for WHO prequalification: The case of the trivalent influenza vaccine manufactured by Instituto Butantan.世卫组织资格预审的药物警戒能力建设：布坦坦研究所生产的三价流感疫苗案例。
Vaccine. 2019 Dec 10;37(52):7560-7565. doi: 10.1016/j.vaccine.2019.09.082. Epub 2019 Oct 4.
4
Reply to the Letter to the Editor by Kessler Y et al. regarding the manuscript "Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.".回复凯斯勒等人致编辑的信，信中涉及手稿《erenumab、galcanezumab和fremanezumab在妊娠和哺乳期的安全性概况：世界卫生组织药物警戒数据库分析》。
Cephalalgia. 2021 Sep;41(10):1130-1131. doi: 10.1177/03331024211006849. Epub 2021 May 2.
5
Letter to the Editor: A Discussion About Pharmacovigilance Study Methods.致编辑的信：关于药物警戒研究方法的讨论。
J Korean Med Sci. 2024 Apr 22;39(15):e142. doi: 10.3346/jkms.2024.39.e142.
6
Active vaccine safety surveillance in low- and middle-income countries: Challenges for vaccine manufacturers from emerging countries.低收入和中等收入国家的主动疫苗安全性监测：新兴国家疫苗制造商面临的挑战
Vaccine. 2025 Feb 27;48:126727. doi: 10.1016/j.vaccine.2025.126727. Epub 2025 Jan 14.
7
Response to Letter to the editor regarding, "Validity, relevance and interpretation of pharmacovigilance disproportionality analyses".对关于“药物警戒不均衡性分析的有效性、相关性及解读”的致编辑信的回复
Bone. 2023 May;170:116704. doi: 10.1016/j.bone.2023.116704. Epub 2023 Feb 11.
8
Role of pharmacovigilance on vaccines control*.药物警戒在疫苗监管中的作用*。
J Rural Med. 2012;7(1):42-5. doi: 10.2185/jrm.7.42. Epub 2012 Jul 7.
9
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.使用个体病例安全报告在药物警戒中进行药物安全性信号检测的不均衡分析报告：方法学开发与声明。
Drug Saf. 2024 Jun;47(6):575-584. doi: 10.1007/s40264-024-01421-9. Epub 2024 May 7.
10
Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers' from emerging countries.新兴国家 34 家疫苗制造商的药物警戒及相关实践的景观分析。
Vaccine. 2020 Jul 22;38(34):5490-5497. doi: 10.1016/j.vaccine.2020.06.016. Epub 2020 Jun 24.
本文引用的文献
1
Concerns on a New Varicella Vaccine Introduced in Korea.
J Med Virol. 2024 Nov;96(11):e70069. doi: 10.1002/jmv.70069.
2
Varicella Vaccine Safety: Absence of Evidence Is Not Evidence of Absence.水痘疫苗安全性：缺乏证据并非没有证据。
J Korean Med Sci. 2024 Sep 9;39(35):e245. doi: 10.3346/jkms.2024.39.e245.
3
A booster administration of the OKA/SK strain causes fatal disseminated varicella in an immunocompetent child.
J Med Virol. 2024 Jul;96(7):e29786. doi: 10.1002/jmv.29786.
4
Immunogenicity and Safety of a Newly Developed Live Attenuated Varicella Vaccine in Healthy Children: A Multi-National, Randomized, Double-Blinded, Active-Controlled, Phase 3 Study.一种新研发的减毒活水痘疫苗在健康儿童中的免疫原性和安全性：一项多国、随机、双盲、活性对照的3期研究。
Vaccines (Basel). 2023 Aug 24;11(9):1416. doi: 10.3390/vaccines11091416.
5
A booster administration of the OKA/SK strain causes fatal disseminated varicella in an immunocompetent child.OKA/SK 株加强免疫可导致免疫功能正常儿童致命性播散性水痘。
J Med Virol. 2023 Sep;95(9):e29108. doi: 10.1002/jmv.29108.
6
Assessment of attenuation of varicella-zoster virus vaccines based on genomic comparison.基于基因组比较的水痘-带状疱疹病毒疫苗减毒评估。
J Med Virol. 2023 Mar;95(3):e28590. doi: 10.1002/jmv.28590.
7
Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.疫苗不良事件报告系统中 2006-2020 年美国水痘疫苗的安全性监测。
J Infect Dis. 2022 Oct 21;226(Suppl 4):S431-S440. doi: 10.1093/infdis/jiac306.
8
Primary and Acquired Immunodeficiencies Associated With Severe Varicella-Zoster Virus Infections.原发性和获得性免疫缺陷与严重水痘-带状疱疹病毒感染相关。
Clin Infect Dis. 2021 Nov 2;73(9):e2705-e2712. doi: 10.1093/cid/ciaa1274.
9
Varicella Virus Vaccine Live: A 22-Year Review of Postmarketing Safety Data.水痘减毒活疫苗：上市后安全性数据的22年回顾
Open Forum Infect Dis. 2019 Aug 1;6(8). doi: 10.1093/ofid/ofz295.
10
Fatal varicella due to the vaccine-strain varicella-zoster virus.由疫苗株水痘-带状疱疹病毒引起的致命性水痘
Hum Vaccin Immunother. 2014;10(1):146-9. doi: 10.4161/hv.26200. Epub 2013 Aug 27.
Zotero 插件